Ardelyx (ARDX) Competitors $6.13 -0.09 (-1.50%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, CRSP, TGTX, and PTCTShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus CRISPR Therapeutics TG Therapeutics PTC Therapeutics Ardelyx (NASDAQ:ARDX) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk. Is ARDX or ABVX more profitable? Abivax has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Abivax's return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-14.60% -36.57% -13.42% Abivax N/A N/A N/A Do analysts prefer ARDX or ABVX? Ardelyx currently has a consensus price target of $11.70, indicating a potential upside of 90.96%. Abivax has a consensus price target of $99.43, indicating a potential upside of 19.97%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10Abivax 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media favor ARDX or ABVX? In the previous week, Ardelyx had 1 more articles in the media than Abivax. MarketBeat recorded 3 mentions for Ardelyx and 2 mentions for Abivax. Abivax's average media sentiment score of 0.97 beat Ardelyx's score of 0.45 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ARDX or ABVX? Ardelyx has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Do institutionals and insiders believe in ARDX or ABVX? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 4.8% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation & earnings, ARDX or ABVX? Ardelyx has higher revenue and earnings than Abivax. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.61M4.43-$39.14M-$0.23-26.64AbivaxN/AN/A-$190.71MN/AN/A SummaryArdelyx beats Abivax on 8 of the 14 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.48B$2.55B$5.75B$10.49BDividend YieldN/A55.05%5.61%4.58%P/E Ratio-26.7223.3676.8726.87Price / Sales4.43713.65552.77128.47Price / CashN/A27.8325.8131.15Price / Book8.395.4013.696.52Net Income-$39.14M$32.95M$3.29B$271.58M7 Day Performance-4.56%4.62%2.37%3.68%1 Month Performance0.28%5.94%4.78%8.16%1 Year Performance3.50%2.32%81.33%27.13% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.2564 of 5 stars$6.13-1.5%$11.70+91.0%+1.5%$1.48B$333.61M-26.7290ABVXAbivax2.5627 of 5 stars$85.87+2.2%$99.43+15.8%+627.5%$6.35BN/A0.0061CYTKCytokinetics4.2543 of 5 stars$49.44-3.3%$75.38+52.5%-10.3%$6.12B$18.47M-9.69250Trending NewsAnalyst ForecastLEGNLegend Biotech3.1743 of 5 stars$33.88+2.3%$74.22+119.1%-29.8%$6.11B$627.24M-38.502,609Positive NewsAXSMAxsome Therapeutics4.8567 of 5 stars$116.78-1.4%$177.86+52.3%+22.6%$5.91B$495.03M-23.03380Insider TradeNUVLNuvalent2.9473 of 5 stars$79.37-1.4%$120.91+52.3%-26.9%$5.80BN/A-16.2040RNAAvidity Biosciences2.0654 of 5 stars$40.22-10.1%$68.94+71.4%-4.8%$5.76B$10.90M-11.30190Analyst ForecastMRUSMerus3.0192 of 5 stars$68.09-2.1%$88.75+30.3%+39.3%$5.26B$36.13M-12.3837Positive NewsCRSPCRISPR Therapeutics2.8866 of 5 stars$57.84+2.8%$71.60+23.8%+28.9%$5.12B$37.31M-10.65460Analyst ForecastTGTXTG Therapeutics4.1958 of 5 stars$31.75-1.3%$46.25+45.7%+41.9%$5.10B$454.07M85.81290PTCTPTC Therapeutics3.8836 of 5 stars$58.98-3.5%$69.00+17.0%+66.1%$4.85B$806.78M8.461,410Positive News Related Companies and Tools Related Companies ABVX Competitors CYTK Competitors LEGN Competitors AXSM Competitors NUVL Competitors RNA Competitors MRUS Competitors CRSP Competitors TGTX Competitors PTCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDX Stock Alerts